ticker nerd logo
Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc Stock Forecast & Price Prediction

Live Vertex Pharmaceuticals Inc Stock (VRTX) Price
$422.91

21

Ratings

  • Buy 13
  • Hold 6
  • Sell 2
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$422.91

P/E Ratio

P/E Ratio not available for VRTX

Volume Traded Today

$1.2M

Dividend

Dividends not available for VRTX

52 Week High/low

448.40/283.60

Vertex Pharmaceuticals Inc Market Cap

$0

🛑 Alert: These ten stocks could have higher potential than $VRTX 🛑

Before you buy VRTX you’ll want to see this list of ten stocks that have huge potential. Want to see if VRTX made the cut? Enter your email below

VRTX Summary

Based on ratings from 21 stock analysts, the Vertex Pharmaceuticals Inc stock price is expected to increase by 2.62% in 12 months. This is calculated by using the average 12-month stock price forecast for Vertex Pharmaceuticals Inc. The lowest target is $325.00 and the highest is $559.00. Please note analyst price targets are not guaranteed and could be missed completely.

VRTX Analyst Ratings

Vertex Pharmaceuticals Inc has a total of 21 Wall St Analyst ratings. There are 13 buy ratings, 6 ratings, and 2 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Vertex Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

VRTX stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

naz rahman
Maxim Group

Hold

None

initiatedcoverage

Feb 6, 2024
brian abrahams
RBC Capital

Hold

$420.0

rated

Feb 5, 2024
william pickering
Bernstein

Hold

$450.0

downgraded

Feb 2, 2024
joseph stringer
Needham

Hold

None

maintained

Jan 30, 2024
terence flynn
Morgan Stanley

Hold

$368.0

maintained

Dec 28, 2023
michael yee
Jefferies

Hold

$385.0

maintained

Dec 19, 2023
sasikarn udomvej
DBS

Hold

$359.0

maintained

Dec 1, 2023
paul matteis
Stifel Nicolaus

Hold

$373.0

maintained

Nov 22, 2023
matthew harrison
Morgan Stanley

Hold

$364.0

maintained

Nov 8, 2023
karen sterling
Westpark Capital

Hold

None

initiatedcoverage

May 25, 2023
danielle brill
Raymond James

Hold

None

maintained

May 3, 2023
do kim
Piper Sandler

Hold

$296.0

rated

Feb 7, 2023
vamil divan
Mizuho Securities

Hold

$265.0

initiatedcoverage

May 22, 2022
jason mccarthy
Maxim Group

Hold

None

maintained

Jul 30, 2021
narumi nakagiri
Daiwa

Hold

$210.0

downgraded

Jun 11, 2021
alan carr
Needham

Hold

None

rated

Oct 30, 2020
joshua schimmer
Evercore ISI

Hold

$270.0

maintained

Jan 31, 2020
ravi mehrotra
Evercore ISI

Hold

$183.0

initiatedcoverage

Apr 11, 2019
marc goodman
SVB Securities

Hold

None

downgraded

Mar 19, 2019
laura chico
Wedbush

Hold

None

downgraded

Jan 2, 2019

VRTX Company Information

VRTX
Vertex Pharmaceuticals Inc (VRTX)

When did it IPO

1991

Staff Count

0

Country

Sector/Industry

/

CEO

Market Cap

$0

Vertex Pharmaceuticals Inc(VRTX) Financial Data

In 2023, VRTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that VRTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.00%
  • Gross profit TTM $0
  • Return on assets TTM 0.00%
  • Return on equity TTM 0.00%
  • Profit margin %
  • Book value 0.00%
  • Market capitalisation $0
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year N/A
  • EPS next year N/A
... ...

Similar Stocks to Vertex Pharmaceuticals Inc VRTX

🛑 Alert: These ten stocks could have higher potential than $VRTX 🛑

Before you buy VRTX you’ll want to see this list of ten stocks that have huge potential. Want to see if VRTX made the cut? Enter your email below

...

VRTX Frequently asked questions

The highest forecasted price for VRTX is $559.00 from salveen richter at Goldman Sachs.

The lowest forecasted price for VRTX is $325.00 from brian skorney from Robert W. Baird

The VRTX analyst ratings consensus are 13 buy ratings, 6 hold ratings, and 2 sell ratings.